Steroid as a modulator of gabaa receptor
AssigneeUmecrine Cognition AB
InventorsTorbjörn BÄCKSTRÖM, Gianna RAGAGNIN, Magnus LÖFGREN, Jessica SJÖSTEDT
Life of this patent
Estimating the term…
Abstract
The present disclosure concerns the use of 3α-ethynyl-3β-hydroxy-5α-androstan-17-one as medicament, in particular in treatment of a disease or disorder associated with an α3 subtype of the GABAA receptor. The present disclosure is specifically concerned treatment of obesity, hyperphagia disorders, Prader-Willi's syndrome, polycystic ovarian syndrome, and/or diabetes. Said invention is also concerned with reducing or preventing overweight.
Claims22
1-15. (canceled)
A method of treating, alleviating and/or preventing a disease or disorder associated with an α3 subtype of a GABAA receptor, comprising administering a pharmaceutically effective amount of 3α-ethynyl-3β-hydroxy-5α-androstan-17-one as shown in Formula 1
- or a pharmaceutically acceptable salt, hydrate, prodrug or solvate thereof, to a patient in need thereof.
32-39. (canceled)
A non-therapeutic method of preventing or reducing overweight in a subject comprising administering a cosmetically effective amount of 3α-ethynyl-3β-hydroxy-5α-androstan-17-one as shown in Formula 1
Dependencies are inferred from the claim text.